{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:10:05Z","timestamp":1789593005409,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001797","name":"Pharmaceutical Research and Manufacturers of America Foundation","doi-asserted-by":"publisher","award":["1335819"],"award-info":[{"award-number":["1335819"]}],"id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R61NS126026"],"award-info":[{"award-number":["R61NS126026"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS120663"],"award-info":[{"award-number":["R01NS120663"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RF1NS131165"],"award-info":[{"award-number":["RF1NS131165"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Pain"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ynpai.2025.100185","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T11:14:28Z","timestamp":1747394068000},"page":"100185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["R and S enantiomers of CBD3063, a CaV2.2\u00a0N-type calcium channel modulator, alleviate capsaicin-induced inflammatory pain"],"prefix":"10.1016","volume":"18","author":[{"given":"Santiago","family":"Loya-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick J.","family":"Rodr\u00edguez-Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Calder\u00f3n-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Perez-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-2969","authenticated-orcid":false,"given":"Rajesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"51","key":"10.1016\/j.ynpai.2025.100185_b0005","doi-asserted-by":"crossref","first-page":"E12043","DOI":"10.1073\/pnas.1811212115","article-title":"Ablation of alpha(2)delta-1 inhibits cell-surface trafficking of endogenous N-type calcium channels in the pain pathway in vivo","volume":"115","author":"Nieto-Rostro","year":"2018","journal-title":"Proc Natl Acad Sci U S a."},{"issue":"5","key":"10.1016\/j.ynpai.2025.100185_b0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2174\/157340606778250216","article-title":"N-type calcium channel blockers: novel therapeutics for the treatment of pain","volume":"2","author":"Schroeder","year":"2006","journal-title":"Med Chem."},{"issue":"7","key":"10.1016\/j.ynpai.2025.100185_b0015","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1097\/j.pain.0000000000001524","article-title":"Targeting the CaValpha-CaVbeta interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy","volume":"160","author":"Khanna","year":"2019","journal-title":"Pain."},{"issue":"4","key":"10.1016\/j.ynpai.2025.100185_b0020","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s00221-002-1217-3","article-title":"Localization of N-type Ca2+ channels in the rat spinal cord following chronic constrictive nerve injury","volume":"147","author":"Cizkova","year":"2002","journal-title":"Exp Brain Res."},{"key":"10.1016\/j.ynpai.2025.100185_b0025","article-title":"Interleukin-1alpha links peripheral Ca(V)2.2 channel activation to rapid adaptive increases in heat sensitivity in skin","volume":"14(1):9051","author":"Salib","year":"2024","journal-title":"Sci Rep."},{"key":"10.1016\/j.ynpai.2025.100185_b0030","doi-asserted-by":"crossref","unstructured":"Hendrich J, Van Minh AT, Heblich F, et al. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin [Research Support, Non-U.S. Gov't]. Proc Natl Acad Sci U S A. 2008;105(9):3628-33.","DOI":"10.1073\/pnas.0708930105"},{"key":"10.1016\/j.ynpai.2025.100185_b0035","doi-asserted-by":"crossref","unstructured":"Bauer CS, Nieto-Rostro M, Rahman W, et al. The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin [Research Support, Non-U.S. Gov't]. J Neurosci. 2009;29(13):4076-88.","DOI":"10.1523\/JNEUROSCI.0356-09.2009"},{"issue":"1","key":"10.1016\/j.ynpai.2025.100185_b0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/nedt.2007.3.1.69","article-title":"Ziconotide: a review of its pharmacology and use in the treatment of pain","volume":"3","author":"McGivern","year":"2007","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"3","key":"10.1016\/j.ynpai.2025.100185_b0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pain.2005.08.013","article-title":"Algorithm for neuropathic pain treatment: an evidence based proposal","volume":"118","author":"Finnerup","year":"2005","journal-title":"Pain."},{"issue":"Suppl 2","key":"10.1016\/j.ynpai.2025.100185_b0050","first-page":"S89","article-title":"Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability","volume":"61","author":"Evoy","year":"2021","journal-title":"J Clin Pharmacol."},{"issue":"1","key":"10.1016\/j.ynpai.2025.100185_b0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.291.1.63","article-title":"Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial","volume":"291","author":"Staats","year":"2004","journal-title":"JAMA."},{"issue":"4","key":"10.1016\/j.ynpai.2025.100185_b0060","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177429","article-title":"C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models","volume":"135","author":"Tang","year":"2024","journal-title":"J Clin Invest."},{"issue":"1","key":"10.1016\/j.ynpai.2025.100185_b0065","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/19336950.2020.1863595","article-title":"Comparison of quinazoline and benzoylpyrazoline chemotypes targeting the CaV\u03b1-\u03b2 interaction as antagonists of the N-type CaV2.2 channel","volume":"15","author":"Ran","year":"2021","journal-title":"Channels (austin)"},{"issue":"7","key":"10.1016\/j.ynpai.2025.100185_b0070","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1097\/j.pain.0000000000001524","article-title":"Targeting the CaV\u03b1-CaV\u03b2 interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy","volume":"160","author":"Khanna","year":"2019","journal-title":"Pain."},{"issue":"1","key":"10.1016\/j.ynpai.2025.100185_b0075","article-title":"CRMP2 and voltage-gated ion channels: potential roles in neuropathic pain. Neuronal","volume":"2","author":"Chew","year":"2018","journal-title":"Signal."},{"issue":"Pt 23","key":"10.1016\/j.ynpai.2025.100185_b0080","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1242\/jcs.053280","article-title":"Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons","volume":"122","author":"Chi","year":"2009","journal-title":"J Cell Sci."},{"issue":"45","key":"10.1016\/j.ynpai.2025.100185_b0085","doi-asserted-by":"crossref","first-page":"31375","DOI":"10.1074\/jbc.M109.009951","article-title":"An atypical role for collapsin response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels","volume":"284","author":"Brittain","year":"2009","journal-title":"J Biol Chem."},{"issue":"7","key":"10.1016\/j.ynpai.2025.100185_b0090","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.2345","article-title":"Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca(2)(+) channel complex","volume":"17","author":"Brittain","year":"2011","journal-title":"Nat Med."},{"issue":"5","key":"10.1016\/j.ynpai.2025.100185_b0095","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4161\/chan.5.5.17363","article-title":"Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex","volume":"5","author":"Wilson","year":"2011","journal-title":"Channels (austin)."},{"issue":"12","key":"10.1016\/j.ynpai.2025.100185_b0100","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1111\/bph.13737","article-title":"Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides","volume":"175","author":"Moutal","year":"2018","journal-title":"Br J Pharmacol."},{"issue":"7","key":"10.1016\/j.ynpai.2025.100185_b0105","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1021\/acsptsci.4c00181","article-title":"Peptide and Peptidomimetic Inhibitors Targeting the Interaction of Collapsin Response Mediator Protein 2 with the N-Type Calcium Channel for Pain Relief","volume":"7","author":"Perez-Miller","year":"2024","journal-title":"ACS Pharmacol Transl Sci."},{"issue":"47","key":"10.1016\/j.ynpai.2025.100185_b0110","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2305215120","article-title":"A peptidomimetic modulator of the Ca(V)2.2 N-type calcium channel for chronic pain","volume":"120","author":"Gomez","year":"2023","journal-title":"Proc Natl Acad Sci U S a."},{"issue":"12","key":"10.1016\/j.ynpai.2025.100185_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2024.104664","article-title":"Uncoupling the CRMP2-Ca(V)2.2 Interaction Reduces Pain-Like Behavior in a Preclinical Joint-Pain Model","volume":"25","author":"Allen","year":"2024","journal-title":"J Pain."},{"issue":"1","key":"10.1016\/j.ynpai.2025.100185_b0120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/jssc.201900649","article-title":"Liquid chromatographic methods for separation, determination, and bioassay of enantiomers of etodolac: A review","volume":"43","author":"Singh","year":"2020","journal-title":"J Sep Sci."},{"issue":"11","key":"10.1016\/j.ynpai.2025.100185_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26113113","article-title":"Enantioselectivity in Drug Pharmacokinetics and Toxicity: Pharmacological Relevance and Analytical Methods","volume":"26","author":"Coelho","year":"2021","journal-title":"Molecules."},{"issue":"10","key":"10.1016\/j.ynpai.2025.100185_b0130","first-page":"1640","article-title":"Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers (author's transl)","volume":"29","author":"Blaschke","year":"1979","journal-title":"Arzneimittelforschung."},{"issue":"33","key":"10.1016\/j.ynpai.2025.100185_b0135","doi-asserted-by":"crossref","first-page":"25296","DOI":"10.1074\/jbc.M110.128801","article-title":"In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation","volume":"285","author":"Wang","year":"2010","journal-title":"J Biol Chem."},{"issue":"3","key":"10.1016\/j.ynpai.2025.100185_b0140","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s12035-015-9141-2","article-title":"(S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5","volume":"53","author":"Moutal","year":"2016","journal-title":"Mol Neurobiol."},{"issue":"1","key":"10.1016\/j.ynpai.2025.100185_b0145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J Neurosci Methods."},{"key":"10.1016\/j.ynpai.2025.100185_b0150","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev.pa.20.040180.002301","article-title":"Efficient analysis of experimental observations","volume":"20","author":"Dixon","year":"1980","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"10.1016\/j.ynpai.2025.100185_b0155","article-title":"Targeting Na(v)1.7 and Na(v)1.8 with a PIKfyve inhibitor to reverse inflammatory and neuropathic pain. Neurobiol","volume":"17","author":"Rodr\u00edguez-Palma","year":"2025","journal-title":"Pain."},{"issue":"3","key":"10.1016\/j.ynpai.2025.100185_b0160","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/pm\/pnv068","article-title":"A randomized, double-blind, placebo-controlled, crossover study of the T-type calcium channel blocker abt-639 in an intradermal capsaicin experimental pain model in healthy adults [Article]","volume":"17","author":"Wallace","year":"2016","journal-title":"Pain Medicine (United States)."},{"issue":"24","key":"10.1016\/j.ynpai.2025.100185_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/cells11244027","article-title":"Pharmacological Profile of MP-101, a Novel Non-racemic Mixture of R- and S-dimiracetam with Increased Potency in Rat Models of Cognition, Depression and Neuropathic Pain","volume":"11","author":"Bonifacino","year":"2022","journal-title":"Cells."},{"issue":"2","key":"10.1016\/j.ynpai.2025.100185_b0170","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.brainresbull.2005.11.017","article-title":"Mirtazapine and its enantiomers differentially modulate acute thermal nociception in rats","volume":"69","author":"Freynhagen","year":"2006","journal-title":"Brain Res Bull."},{"issue":"4","key":"10.1016\/j.ynpai.2025.100185_b0175","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.pbb.2008.05.011","article-title":"Effects of norketamine enantiomers in rodent models of persistent pain","volume":"90","author":"Holtman","year":"2008","journal-title":"Pharmacol Biochem Behav."},{"issue":"2","key":"10.1016\/j.ynpai.2025.100185_b0180","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S1526-5900(00)90098-1","article-title":"Enantioselective relief of neuropathic pain by sytemic mexiletine in the rat","volume":"1","author":"Sinnott","year":"2000","journal-title":"The Journal of Pain."},{"issue":"7","key":"10.1016\/j.ynpai.2025.100185_b0185","doi-asserted-by":"crossref","first-page":"760","DOI":"10.2174\/156802611795165098","article-title":"The significance of chirality in drug design and development","volume":"11","author":"Brooks","year":"2011","journal-title":"Curr Top Med Chem."},{"key":"10.1016\/j.ynpai.2025.100185_b0190","doi-asserted-by":"crossref","unstructured":"Ceramella JL, Domenico; Franchini, Angelica; De Luca, Michele; Saturnino, Carmela; Andreu, Inmaculada; Sinicropi, Maria S.; Catalano, Alessia. A look at the importance of chirality in drug activity: Some significative examples. Applied sciences. 2022;12(21):10909.","DOI":"10.3390\/app122110909"},{"issue":"1","key":"10.1016\/j.ynpai.2025.100185_b0195","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1081\/DMR-200047999","article-title":"Enantioselective pharmacokinetics of ibuprofen and involved mechanisms","volume":"37","author":"Hao","year":"2005","journal-title":"Drug Metab Rev."},{"issue":"2","key":"10.1016\/j.ynpai.2025.100185_b0200","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-3565(25)23426-7","article-title":"Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans","volume":"249","author":"Baillie","year":"1989","journal-title":"J Pharmacol Exp Ther."},{"issue":"1","key":"10.1016\/j.ynpai.2025.100185_b0205","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41467-017-02811-7","article-title":"Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation","volume":"9","author":"Zheng","year":"2018","journal-title":"Nat Commun."},{"issue":"7870","key":"10.1016\/j.ynpai.2025.100185_b0210","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-021-03699-6","article-title":"Structure of human Ca(v)2.2 channel blocked by the painkiller ziconotide","volume":"596","author":"Gao","year":"2021","journal-title":"Nature."}],"container-title":["Neurobiology of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452073X25000078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452073X25000078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:39:34Z","timestamp":1789591174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452073X25000078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"alternative-id":["S2452073X25000078"],"URL":"https:\/\/doi.org\/10.1016\/j.ynpai.2025.100185","relation":{},"ISSN":["2452-073X"],"issn-type":[{"value":"2452-073X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"R and S enantiomers of CBD3063, a CaV2.2\u00a0N-type calcium channel modulator, alleviate capsaicin-induced inflammatory pain","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Pain","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ynpai.2025.100185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100185"}}